Shef-3
The cell line is not validated yet.
UOSe003-A
General
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA104628041 |
Ethics
Was the embryo established purely for research purposes? | No |
Have both parents consented to the use of the embryo for ESC derivation? | Yes |
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | |
Alternatives to consent are available? | Yes |
Alternatives to consent | |
Alternative consent approval number | NIHhESC-10-0077 |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | HFEA |
Approval number | R0115-5-A |
hESC Derivation
Date of derivation | 2005-03-30 |
Embryo stage | Blastula with ICM and Trophoblast |
Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
PGD Embryo? |
No |
Derived under xeno-free conditions? |
No |
Derivation under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Non coated |
Feeder cells |
mouse feeders |
Passage method | Mechanically |
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
|
|||
SSEA-1 |
No |
|
|
|||
SSEA-3 |
Yes |
|
|
|||
SSEA-4 |
Yes |
|
|
|||
TRA 1-60 |
Yes |
|
|
|||
TRA 1-81 |
Yes |
|
|
|||
DNMT3B |
Yes |
|
||||
GABRB3 |
Yes |
|
||||
GDF3 |
Yes |
|
||||
NANOG |
Yes |
|
||||
ZFP42 (REX-1) |
Yes |
|
||||
TDGF1 |
Yes |
|
||||
Alkaline Phosphatase |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46XY
Passage number: 4+9
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.